Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Placental protein-13 (PP13) in combination with PAPP-A and free leptin index (fLI) in first trimester maternal serum screening for severe and early preeclampsia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Development and validation of a mass spectrometry-based assay for quantification of insulin-like factor 3 in human serum

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Individual values of antineutrophil cytoplasmic antibodies do not correspond between antigen-specific assays

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  1. Magnetic Resonance Imaging: A New Tool to Optimize the Prediction of Fetal Anemia?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Copenhagen Baby Heart Study: a population study of newborns with prenatal inclusion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Placental protein-13 (PP13) is involved in placental invasion and has been suggested as a maternal serum marker of preeclampsia (PE) development. However, the discriminatory ability of PP13 in first trimester has not been completely clarified.

METHODS: PP13 was measured in first trimester (week 10+3-13+6) maternal serum from 120 PE pregnancies and 267 control pregnancies and was correlated with clinical parameters. The population screening performance of PP13 in combination with the PE markers pregnancy associated plasma protein A (PAPPA) and free leptin index (fLI) was assessed by Monte Carlo simulation.

RESULTS: In severe PE (including HELLP) cases (n=26) the median PP13 concentration was 35.8 pg/mL (range: 17.8-85.5 pg/mL) and in PE pregnancies (n=10) with birth prior to week 34, the median PP13 concentration was 30.6 pg/mL (13.1-50.1 pg/mL), compared to controls with a median of 54.8 pg/mL (range: 15.4-142.6 pg/mL) (p<0.04). The population screening detection rate (DR) for a false-positive rate of 10% for severe PE and HELLP was 26% for PP13, 28% for PP13+PAPP-A, 33% for PP13+fLI, and 40% for PP13+PAPP-A+fLI.

CONCLUSIONS: PP13 is a marker of severe PE and HELLP syndrome. The screening performance of PP13 can be markedly improved by combining it with fLI and PAPP-A.

OriginalsprogEngelsk
TidsskriftClinical Chemistry and Laboratory Medicine
Vol/bind56
Udgave nummer1
Sider (fra-til)65-74
ISSN1434-6621
DOI
StatusUdgivet - 2017

ID: 51603514